Vizsgálati helyszín
Brain Research Center Den Bosch B.V.
's-Hertogenbosch, North Brabant 5223 LA, HollandiaMég nincs intézményhez kötve
- 16futó vizsgálat
- 18lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 34 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis14 vizsgálat
- 3. fázis14 vizsgálat
- 1. fázis5 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult18 vizsgálat
- Toboroz8 vizsgálat
- Fut, nem toboroz4 vizsgálat
- Még nem toboroz4 vizsgálat
- Fő szponzor
- Novo Nordisk A/S4 vizsgálat
- Hoffmann-La Roche3 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Glaxosmithkline Research & Development Limited2 vizsgálat
- és még 20
Futó vizsgálatok
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Roel Mocking (principal investigator)
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321
2025-524053-14-00· 1. fázis· Lycia Therapeutics Inc.· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451· 1. fázis· Denali Therapeutics Inc.· Forrás
Fut, nem toboroz
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727· 1. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
2024-511110-21-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· 2. fázis· Novartis Pharma AG· Forrás
Lezárult
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Lezárult
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Characterization of Immune Response in Participants from a Posdinemab Study
2024-514634-20-00· 1. fázis· Janssen Cilag International· Forrás
Lezárult
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· 2. fázis· PRInnovation GmbH· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Lezárult
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
2023-504373-20-00· 2. fázis· Eip Pharma Inc.· Forrás
Lezárult
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· 2. fázis· GemVax & Kael· Forrás
Lezárult
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· 2. fázis· UCB Biopharma SRL· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
NCT04464564· 3. fázis· Otsuka Pharmaceutical Development & Commercialization Inc.· Forrás
Lezárult
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· 2. fázis· Janssen - Cilag International· Forrás
Lezárult
A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4).
2024-515858-25-00· 2. fázis· Alzheon Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek